C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00688454
First received: May 29, 2008
Last updated: April 8, 2009
Last verified: April 2009
  Purpose

The study explores efficacy and safety of the lipid-lowering therapy with CRESTOR in statin-naive patients and in patients with previously unsuccessful statin therapy. This study was designed to investigate the dynamic of the lipid parameters and therapy tolerability during 8-10 weeks treatment with CRESTOR


Condition
Hypercholesteremia

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • LDL-Cholesterin, HDL-Cholesterin, Triglycerides, Total Cholesterin [ Time Frame: 3 visits within 10 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Tolerability of CRESTOR-therapy [ Time Frame: 3 visits within 10 weeks ] [ Designated as safety issue: No ]

Enrollment: 3392
Study Start Date: February 2007
Study Completion Date: January 2008
Groups/Cohorts
Pt with hypercholesteremia
Patients treated with CRESTOR because of hypercholesteremia

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Statin-naive patients and unsuccessfully treated with other (non rosubastatin) statins patients

Criteria

Inclusion Criteria:

  • Patients with hypercholesteremia who was never treated with statins before
  • Patient with hypercholesteremia who was treated with a statin (other then rosuvastatin) but because of its adverse effects/insufficient action was switched to therapy with CRESTOR

Exclusion Criteria:

  • None
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Dr med Madeleine Billeter, AstraZeneca AG, Switzerland
ClinicalTrials.gov Identifier: NCT00688454     History of Changes
Other Study ID Numbers: NIS-CCH-CRE-2007/1
Study First Received: May 29, 2008
Last Updated: April 8, 2009
Health Authority: Switzerland: Ethikkommission

Keywords provided by AstraZeneca:
Hyperlipidemia
Rosuvastatin
Efficacy
tolerability
CRESTOR therapy

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Rosuvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Enzyme Inhibitors
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 29, 2014